HAOHAI BIOTEC(SH:688366) Guo Ji Jin Rong Bao·2025-09-18 03:44Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) is facing potential regulatory penalties due to insider trading allegations against its controlling shareholder Jiang Wei, although the company asserts that this matter will not significantly impact its operations or financials [1][3]. Group 1: Company Structure and Shareholding - Jiang Wei and his spouse You Jie are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [3]. - The regulatory penalty is directed solely at Jiang Wei, and the company clarifies that the issue is unrelated to its business operations [3]. Group 2: Business Overview and Financial Performance - Haohai Biological is a prominent producer of hyaluronic acid in China, operating in four main sectors: aesthetic medicine, ophthalmology, orthopedics, and hemostasis [3]. - In 2024, the revenue breakdown by product category shows that aesthetic medicine accounts for 44.30%, ophthalmic products 31.79%, and orthopedic products 16.92% [3]. - The ophthalmology segment is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [3]. - For the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [3].